Atria Wealth Solutions Inc. Has $80,000 Position in Aurinia Pharmaceuticals Inc $AUPH

Atria Wealth Solutions Inc. lowered its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 33.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,000 shares of the biotechnology company’s stock after selling 5,000 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Aurinia Pharmaceuticals were worth $80,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth approximately $27,000. Tower Research Capital LLC TRC grew its position in Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after buying an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $31,000. GAMMA Investing LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,744 shares in the last quarter. Finally, Natixis acquired a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $49,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AUPH. Royal Bank Of Canada raised their target price on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an “outperform” rating in a report on Friday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th.

Aurinia Pharmaceuticals Trading Up 1.5%

Shares of AUPH stock opened at $12.27 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. Aurinia Pharmaceuticals Inc has a fifty-two week low of $5.51 and a fifty-two week high of $12.48. The company has a market cap of $1.62 billion, a PE ratio of 28.54 and a beta of 1.23. The stock’s fifty day moving average price is $9.08 and its two-hundred day moving average price is $8.39.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.01). The firm had revenue of $70.01 million for the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Equities analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Insider Transactions at Aurinia Pharmaceuticals

In related news, Director Kevin Tang bought 1,000,000 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was acquired at an average cost of $10.12 per share, with a total value of $10,120,000.00. Following the transaction, the director directly owned 11,029,500 shares in the company, valued at approximately $111,618,540. This trade represents a 9.97% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders acquired 1,300,000 shares of company stock worth $13,590,000. 12.20% of the stock is owned by company insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.